Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer.

IMPORTANCE More patients with cancer use hospice currently than ever before, but there are indications that care intensity outside of hospice is increasing, and length of hospice stay decreasing. Uncertainties regarding how hospice affects health care utilization and costs have hampered efforts to promote it. OBJECTIVE To compare utilization and costs of health care for patients with poor-prognosis cancers enrolled in hospice vs similar patients without hospice care. DESIGN, SETTING, AND PARTICIPANTS Matched cohort study of patients in hospice and nonhospice care using a nationally representative 20% sample of Medicare fee-for-service beneficiaries who died in 2011. Patients with poor-prognosis cancers (eg, brain, pancreatic, metastatic malignancies) enrolled in hospice before death were matched to similar patients who died without hospice care. EXPOSURES Period between hospice enrollment and death for hospice beneficiaries, and the equivalent period of nonhospice care before death for matched nonhospice patients. MAIN OUTCOMES AND MEASURES Health care utilization including hospitalizations and procedures, place of death, cost trajectories before and after hospice start, and cumulative costs, all during the last year of life. RESULTS Among 86,851 patients with poor-prognosis cancers, median time from first poor-prognosis diagnosis to death was 13 months (interquartile range [IQR], 3-34), and 51,924 patients (60%) entered hospice before death. Matching yielded a cohort balanced on age, sex, region, time from poor-prognosis diagnosis to death, and baseline care utilization, with 18,165 patients in the hospice group and 18,165 in the nonhospice group. After matching, 11% of nonhospice and 1% of hospice beneficiaries who had cancer-directed therapy after exposure were excluded. Median hospice duration was 11 days. After exposure, nonhospice beneficiaries had significantly more hospitalizations (65% [95% CI, 64%-66%], vs hospice with 42% [95% CI, 42%-43%]; risk ratio, 1.5 [95% CI, 1.5-1.6]), intensive care (36% [95% CI, 35%-37%], vs hospice with 15% [95% CI, 14%-15%]; risk ratio, 2.4 [95% CI, 2.3-2.5]), and invasive procedures (51% [95% CI, 50%-52%], vs hospice with 27% [95% CI, 26%-27%]; risk ratio, 1.9 [95% CI, 1.9-2.0]), largely for acute conditions not directly related to cancer; and 74% (95% CI, 74%-75%) of nonhospice beneficiaries died in hospitals and nursing facilities compared with 14% (95% CI, 14%-15%) of hospice beneficiaries. Costs for hospice and nonhospice beneficiaries were not significantly different at baseline, but diverged after hospice start. Total costs over the last year of life were $71,517 (95% CI, $70,543-72,490) for nonhospice and $62,819 (95% CI, $62,082-63,557) for hospice, a statistically significant difference of $8697 (95% CI, $7560-$9835). CONCLUSIONS AND RELEVANCE In this sample of Medicare fee-for-service beneficiaries with poor-prognosis cancer, those receiving hospice care vs not (control), had significantly lower rates of hospitalization, intensive care unit admission, and invasive procedures at the end of life, along with significantly lower total costs during the last year of life.

[1]  S. Stearns,et al.  Medicare's hospice benefit: analysis of utilization and resource use. , 2014, Medicare & medicaid research review.

[2]  P. Deb,et al.  Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. , 2013, Health affairs.

[3]  Klim McPherson,et al.  Observational intensity bias associated with illness adjustment: cross sectional analysis of insurance claims , 2013, BMJ : British Medical Journal.

[4]  Vincent Mor,et al.  Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. , 2013, JAMA.

[5]  M. Tinetti.  The retreat from advanced care planning. , 2012, JAMA.

[6]  D. Meier,et al.  Increased access to palliative care and hospice services: opportunities to improve value in health care. , 2011, The Milbank quarterly.

[7]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[8]  D. Casarett.  Rethinking hospice eligibility criteria. , 2011, JAMA.

[9]  G. King,et al.  Multivariate Matching Methods That Are Monotonic Imbalance Bounding , 2011 .

[10]  P. Maciejewski,et al.  Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. , 2008, JAMA.

[11]  Thomas J. Smith,et al.  The role of chemotherapy at the end of life: "when is enough, enough?". , 2008, JAMA.

[12]  K. Steinhauser,et al.  What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? , 2007, Social science & medicine.

[13]  C. Klabunde,et al.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. , 2007, Annals of epidemiology.

[14]  Xianglin L. Du,et al.  External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart Reviews , 2006, Medical care.

[15]  M. Mcclellan,et al.  Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life. , 2004, Health services research.

[16]  Vincent Mor,et al.  Family perspectives on end-of-life care at the last place of care. , 2004, JAMA.

[17]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[18]  M. Maltoni,et al.  Prognosis in advanced cancer. , 2002, Hematology/oncology clinics of North America.

[19]  J. Newhouse,et al.  Providing care at the end of life: do Medicare rules impede good care? , 2001, Health affairs.

[20]  Nicholas Christakis,et al.  In Search of a Good Death: Observations of Patients, Families, and Providers , 2000, Annals of Internal Medicine.

[21]  William A. Knaus,et al.  A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. , 1995, JAMA.

[22]  Pall Med,et al.  Dying in America: improving quality and honoring individual preferences near the end of life. , 2015, Military medicine.